To substantiate our hypothesis that AURKB inhibition with barasertib attenuates pulmonary fibrosis, we used an alternative mouse model of bleomycin‐induced pulmonary fibrosis (Singh et al, 2017; Sontake et al, 2018). The gene discussed is AURKB; the disease is pulmonary fibrosis.